JP2018531905A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531905A5 JP2018531905A5 JP2018511451A JP2018511451A JP2018531905A5 JP 2018531905 A5 JP2018531905 A5 JP 2018531905A5 JP 2018511451 A JP2018511451 A JP 2018511451A JP 2018511451 A JP2018511451 A JP 2018511451A JP 2018531905 A5 JP2018531905 A5 JP 2018531905A5
- Authority
- JP
- Japan
- Prior art keywords
- thymosin
- composition containing
- container
- containing thymosin
- inert gas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 claims description 19
- 102100035000 Thymosin beta-4 Human genes 0.000 claims description 18
- 108010079996 thymosin beta(4) Proteins 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- WMFHUUKYIUOHRA-UHFFFAOYSA-N (3-phenoxyphenyl)methanamine;hydrochloride Chemical compound Cl.NCC1=CC=CC(OC=2C=CC=CC=2)=C1 WMFHUUKYIUOHRA-UHFFFAOYSA-N 0.000 claims description 2
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 claims description 2
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- DGPIGKCOQYBCJH-UHFFFAOYSA-M sodium;acetic acid;hydroxide Chemical compound O.[Na+].CC([O-])=O DGPIGKCOQYBCJH-UHFFFAOYSA-M 0.000 claims description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 7
- 239000011261 inert gas Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000004743 Polypropylene Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 229910052786 argon Inorganic materials 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 229920001684 low density polyethylene Polymers 0.000 claims 1
- 239000004702 low-density polyethylene Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- -1 polypropylene Polymers 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 238000007789 sealing Methods 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150140489 | 2015-10-06 | ||
| KR10-2015-0140489 | 2015-10-06 | ||
| PCT/KR2015/013981 WO2017061663A1 (ko) | 2015-10-06 | 2015-12-18 | 티모신 베타 4를 포함하는 안약의 제조방법 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020109496A Division JP2020183391A (ja) | 2015-10-06 | 2020-06-25 | チモシンベータ4を含む眼科用製剤の製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531905A JP2018531905A (ja) | 2018-11-01 |
| JP2018531905A5 true JP2018531905A5 (enExample) | 2021-10-21 |
| JP6996713B2 JP6996713B2 (ja) | 2022-02-04 |
Family
ID=58487995
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511451A Active JP6996713B2 (ja) | 2015-10-06 | 2015-12-18 | チモシンベータ4を含む眼科用製剤の製造方法 |
| JP2020109496A Pending JP2020183391A (ja) | 2015-10-06 | 2020-06-25 | チモシンベータ4を含む眼科用製剤の製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020109496A Pending JP2020183391A (ja) | 2015-10-06 | 2020-06-25 | チモシンベータ4を含む眼科用製剤の製造方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10744088B2 (enExample) |
| EP (1) | EP3342398A4 (enExample) |
| JP (2) | JP6996713B2 (enExample) |
| KR (1) | KR102487614B1 (enExample) |
| HK (1) | HK1256595A1 (enExample) |
| WO (1) | WO2017061663A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210251970A1 (en) | 2018-10-10 | 2021-08-19 | Presbyopia Therapies Inc | Compositions and methods for storage stable ophthalmic drugs |
| CA3114204A1 (en) * | 2018-10-10 | 2020-04-16 | Presbyopia Therapies, Inc. | Compositions and methods for the treatment of presbyopia |
| CN112107678B (zh) * | 2020-09-30 | 2022-11-18 | 辰欣药业股份有限公司 | 一种含有胸腺法新的冻干组合物及其制备方法 |
| US12180206B2 (en) | 2021-11-17 | 2024-12-31 | Lenz Therapeutics Operations, Inc. | Aceclidine derivatives, compositions thereof and methods of use thereof |
| US12414942B1 (en) | 2024-03-15 | 2025-09-16 | Lenz Therapeutics Operations, Inc. | Compositions, methods, and systems for treating presbyopia |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4150744A (en) * | 1976-02-27 | 1979-04-24 | Smith & Nephew Pharmaceuticals Ltd. | Packaging |
| US6271216B1 (en) * | 1989-07-24 | 2001-08-07 | Allergan | Stable solution of hyaluronate in a balanced salt medium |
| KR19980703582A (ko) * | 1995-04-04 | 1998-11-05 | 가와구치 시게키 | 염산 프로카테롤 수용액 제제를 보지하는 패키지 및 염산 프로카테롤 수용액 제제 |
| CA2338928A1 (en) | 1998-07-30 | 2000-02-10 | Hynda K. Kleinman | Thymosin .beta.4 promotes wound repair |
| MXPA01003729A (es) * | 1998-10-14 | 2002-05-06 | Kyowa Hakko Kogyo Kk | Metodo para estabilizar una solucion acuosa de derivados de pirazoloacridona. |
| MX2007001181A (es) * | 2004-07-30 | 2007-03-21 | Otsuka Pharma Co Ltd | Botella comprimible y envase con gotero oftalmico que usa el mismo. |
| CN1748704B (zh) * | 2004-09-15 | 2011-05-04 | 尼普洛株式会社 | 注射用水溶液制剂及其稳定化方法 |
| CA2612522A1 (en) * | 2005-06-17 | 2006-12-28 | Regenerx Biopharmaceuticals, Inc. | Lkktet and/or lkktnt peptide compositions and methods |
| ES2288118B1 (es) * | 2006-05-10 | 2008-11-01 | Bcn Peptides, S.A. | Procedimiento para sintetizar timosinas. |
| WO2008108927A2 (en) * | 2007-03-06 | 2008-09-12 | Regenerx Biopharmaceuticals, Inc. | Methods and compositions for stabilizing polypeptides |
| MX2009010977A (es) | 2007-04-11 | 2010-02-12 | Biomarin Pharm Inc | Metodos de administracion de tetrahidrobiopterina, composiciones asociadas y metodos de medicion. |
| JP5990880B2 (ja) * | 2011-08-31 | 2016-09-14 | 東レ株式会社 | 有用タンパク質組成物およびその製造方法 |
-
2015
- 2015-12-18 HK HK18115713.4A patent/HK1256595A1/en unknown
- 2015-12-18 JP JP2018511451A patent/JP6996713B2/ja active Active
- 2015-12-18 WO PCT/KR2015/013981 patent/WO2017061663A1/ko not_active Ceased
- 2015-12-18 KR KR1020150182196A patent/KR102487614B1/ko active Active
- 2015-12-18 EP EP15905904.7A patent/EP3342398A4/en active Pending
- 2015-12-18 US US15/752,118 patent/US10744088B2/en active Active
-
2020
- 2020-06-25 JP JP2020109496A patent/JP2020183391A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531905A5 (enExample) | ||
| CN103476397B (zh) | 一种制备用于注射的含培美曲塞或其盐的无抗氧化剂溶液形式的药物制剂的方法 | |
| JP2018502910A5 (enExample) | ||
| JP2014518844A5 (enExample) | ||
| RS57044B1 (sr) | Postupak za proizvodnju stabilnog, injektabilnog rastvora noradrenalina niske koncentracije | |
| CN105472996A (zh) | 氢负离子内含物的制备方法及利用其来制备的氢负离子内含物 | |
| JP6505114B2 (ja) | 抗酸化剤を含有しない薬学組成物およびその製造方法 | |
| TW201726611A (zh) | 抑制二甲亞碸之分解的方法 | |
| CN105616343A (zh) | 一种硫辛酸注射液及其制备方法 | |
| CN108338988A (zh) | 碳酸氢钠林格注射液及制备方法 | |
| JP6873923B2 (ja) | 安定化された薬学組成物およびその製造方法 | |
| CN103068397B (zh) | 医用溶液用浓缩物、其制造以及其在透析中的应用 | |
| CN105919931B (zh) | 一种稳定的盐酸法舒地尔注射液及其制备方法 | |
| CN103848763B (zh) | 采用有机羧酸或有机羧酸盐添加剂改变牛磺酸晶体形态的方法 | |
| KR20160002572A (ko) | 고순도 수산화 리튬 수용액의 제조 방법 및 이를 이용한 염수로부터 탄산 리튬의 효율적 추출 방법 | |
| AU2015317229B2 (en) | Dialysis solution | |
| RU2015100257A (ru) | Композиции, содержащие халькогениды, и связанные способы | |
| CN101180051B (zh) | 多利培南水溶液的制备方法 | |
| JPS62194861A (ja) | 液状医薬品包装体 | |
| CN109264746A (zh) | 一种药用级碳酸氢钠的制备方法 | |
| JP7519108B2 (ja) | 医薬組成物及びその製造方法 | |
| CN103936825B (zh) | 邻苯二甲酰-l-丙氨酰-l-谷氨酰胺的绿色制备方法 | |
| NO327263B1 (no) | Parenterale formuleringer som inneholder 10-hydroksy-10,11-tetrahydrokarbamazepin, enhetsdoseringsform og beholder inneholdende nevnte parenterale formulering, samt anvendelse av nevnte parenterale formulering. | |
| CN107049939A (zh) | 一种离子vc口服液及其制备方法 | |
| JP2010047482A (ja) | エダラボン注射液 |